1. Ceftazidime-avibactam in ceftazidime-resistant infections. Issue 9 (September 2016) Authors: Carmeli, Yehuda; Armstrong, Jon; Newell, Paul; Stone, Greg; Wardman, Angela Journal: Lancet infectious diseases Issue: Volume 16:Issue 9(2016:Sep.) Page Start: 997 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Issue 6 (June 2016) Authors: Carmeli, Yehuda; Armstrong, Jon; Laud, Peter J; Newell, Paul; Stone, Greg; Wardman, Angela; Gasink, Leanne B Journal: Lancet infectious diseases Issue: Volume 16:Issue 6(2016:Jun.) Page Start: 661 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Issue 10212 (23rd November 2019) Authors: Paz-Ares, Luis; Dvorkin, Mikhail; Chen, Yuanbin; Reinmuth, Niels; Hotta, Katsuyuki; Trukhin, Dmytro; Statsenko, Galina; Hochmair, Maximilian J; Özgüroğlu, Mustafa; Ji, Jun Ho; Voitko, Oleksandr; Poltoratskiy, Artem; Ponce, Santiago; Verderame, Francesco; Havel, Libor; Bondarenko, Igor; Kazarnowic... Journal: Lancet Issue: Volume 394:Issue 10212(2019) Page Start: 1929 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Issue 10212 (23rd November 2019) Authors: Paz-Ares, Luis; Dvorkin, Mikhail; Chen, Yuanbin; Reinmuth, Niels; Hotta, Katsuyuki; Trukhin, Dmytro; Statsenko, Galina; Hochmair, Maximilian J; Özgüroğlu, Mustafa; Ji, Jun Ho; Voitko, Oleksandr; Poltoratskiy, Artem; Ponce, Santiago; Verderame, Francesco; Havel, Libor; Bondarenko, Igor; Kazarnowic... Journal: Lancet Issue: Volume 394:Issue 10212(2019) Page Start: 1929 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Issue 1 (January 2021) Authors: Goldman, Jonathan W; Dvorkin, Mikhail; Chen, Yuanbin; Reinmuth, Niels; Hotta, Katsuyuki; Trukhin, Dmytro; Statsenko, Galina; Hochmair, Maximilian J; Özgüroğlu, Mustafa; Ji, Jun Ho; Garassino, Marina Chiara; Voitko, Oleksandr; Poltoratskiy, Artem; Ponce, Santiago; Verderame, Francesco; Havel, Libo... Journal: Lancet oncology Issue: Volume 22:Issue 1(2021) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Long-term Clinical Outcomes and Health Care Utilization After Bariatric Surgery: A Population-based Study. Issue 1 (July 2015) Authors: Morgan, David J. R.; Ho, Kwok M.; Armstrong, Jon; Litton, Edward Journal: Annals of surgery Issue: Volume 262:Issue 1(2015:Jul.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Randomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. Issue 5 (25th August 2015) Authors: Das, Shampa; Li, Jianguo; Armstrong, Jon; Learoyd, Maria; Edeki, Timi Journal: Pharmacology research & perspectives Issue: Volume 3:Issue 5(2015:Oct) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Randomized, placebo‐controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime–avibactam or ceftaroline fosamil–avibactam. (22nd October 2013) Authors: Das, Shampa; Armstrong, Jon; Mathews, David; Li, Jianguo; Edeki, Timi Journal: Journal of clinical pharmacology Issue: Volume 54:Number 3(2014:Mar.) Page Start: 331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗